Cladribine + Placebo + Microgynon®
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsing Multiple Sclerosis (RMS)
Conditions
Relapsing Multiple Sclerosis (RMS)
Trial Timeline
Jan 17, 2019 → Sep 16, 2022
NCT ID
NCT03745144About Cladribine + Placebo + Microgynon®
Cladribine + Placebo + Microgynon® is a phase 1 stage product being developed by Merck for Relapsing Multiple Sclerosis (RMS). The current trial status is completed. This product is registered under clinical trial identifier NCT03745144. Target conditions include Relapsing Multiple Sclerosis (RMS).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03745144 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsing Multiple Sclerosis (RMS)